Liver scan changes may foretell deadly complications

NCT ID NCT07739901

Ongoing Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This study looks at medical records from 10,000 adults with MASLD or MASH, a common liver condition. Researchers will check if changes in liver stiffness, measured by a non-invasive scan called FibroScan, are linked to future serious liver problems like cirrhosis, liver cancer, or death. The goal is to see if this simple measurement can help predict who is at highest risk, potentially improving how the disease is monitored and treated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors use routine liver scans to better predict who is at risk of serious liver complications, guiding earlier and more personalized care.
What could go wrong: This is an observational study, so it can show links but not prove cause and effect. The results may also be specific to the Korean population and may not apply to other groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MASLD/MASH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MASLD/MASH

Contacts and locations

Locations

Novo Nordisk Investigational Site

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.